

CHEMICAL FINANCIAL CORP  
Form 8-K  
January 23, 2017

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **January 17, 2017**

**Chemical Financial Corporation**

(Exact Name of Registrant as  
Specified in its Charter)

**Michigan**                      **000-08185**    **38-2022454**  
(State or Other Jurisdiction) (Commission (IRS Employer  
of Incorporation)              File Number) Identification No.)

**235 E. Main Street  
Midland, Michigan**

(Address of Principal Executive Offices) **48640**  
(Zip Code)

Registrant's telephone number, including area code: **(989) 839-5350**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On January 17, 2017, Jeffrey L. Tate was appointed to the Board of Directors of Chemical Financial Corporation ("Chemical") effective March 1, 2017. It is expected that Mr. Tate will be appointed to the Audit Committee and the Risk Management Committee.

Mr. Tate is not a party to any transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K. There is no arrangement or understanding pursuant to which Mr. Tate was selected as a director.

Mr. Tate will be entitled to receive compensation for his service as a director consistent with the compensation paid to other directors as described in Chemical's Proxy Statement for Chemical's April 18, 2016 annual meeting of shareholders.

**Item 7.01 Regulation FD Disclosure.**

On January 23, 2017, Chemical issued the press release attached as Exhibit 99.1 to this Form 8-K, which is here incorporated by reference. The information under this Item 7.01 and the Exhibit are furnished to, and not filed with, the Commission.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits:

99.1 Press Release dated January 23, 2017. This Exhibit is furnished to, and not filed with, the Commission.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 23, 2017 CHEMICAL FINANCIAL CORPORATION  
(Registrant)

/s/ David B. Ramaker  
David B. Ramaker  
Chief Executive Officer and President

EXHIBIT INDEX

Exhibit  
Number

Document

99.1

Press Release dated January 23, 2017. This Exhibit is furnished to, and not filed with, the Commission.